Research on prostate cancer biology, detection, and outcomes. Covers genetic clues, DNA damage, diet and survival, and screening awareness.
Researchers have identified a genetic mutation associated with an increased risk of prostate cancer in African-American and Latino men, with a five times greater risk compared to those without the mutation. The mutation affects the enzyme steroid 5a-reductase, leading to increased production of dihydrotestosterone, a potent form of tes...
Scientists found that osteonectin, a bone protein, attracts prostate cancer cells and stimulates their invasion. This discovery has important implications for the treatment of prostate cancer and other bone-seeking cancers.
Researchers are focusing on two isoflavones in soy: genistein and daidzein. Preliminary evidence suggests that predominantly daidzein may be of greater cardiovascular benefit.
UI researchers found that restoring E-cadherin protein hinders prostate cancer spread and enhances cell adhesion. The study provides a potential new approach to target invasive prostate cancer.
New research suggests that PSA testing alone cannot fully explain the decline in prostate cancer deaths since the early 1990s. Instead, other factors such as changing treatment patterns and misclassification of cause of death may be contributing to the trend.
Researchers will discuss cellular interactions in prostate cancer, new gene discoveries, and techniques for measuring patient outcomes. The symposium also features presentations on experimental agents, immunotherapies, and alternative therapies for treating prostate cancer.
A USCF study reveals that an herbal therapy, PC-SPES, significantly reduces prostate-specific antigen (PSA) levels by more than 50% in men with advanced prostate cancer. The compound, containing eight Chinese herbs including saw palmetto, showed promising results in both hormone-naïve and hormone-resistant patients.
Researchers at Thomas Jefferson University have found that radiation therapy helps patients with localized prostate cancer live longer. After examining the results of 1560 patients who received radiation therapy alone for prostate cancer, they discovered that those with high-risk disease benefited the most from higher doses of radiation.
A new study developed a simple method to assess the risk of deadly metastatic cancer in men after prostate removal. The chart uses three common measures, including Gleason score and PSA doubling time, to pinpoint the risk for developing metastatic cancer.
Research at Ohio State University found that a low-calorie diet slowed tumor growth in rats and mice with prostate cancer. The study suggested that maintaining proper energy balance may inhibit prostate cancer progression.
Researchers at the Fred Hutchinson Cancer Research Center and the University of Washington have mapped a gene associated with prostate cancer that runs in families, also linked to primary brain cancer. The study results appear in the American Journal of Human Genetics.
A national pilot study is testing whether soy supplementation can reduce prostate cancer risk in African-American men. The $494,588 study, led by Electra D. Paskett, Ph.D., will evaluate the effect of soy on markers for prostate cancer risk and assess its impact on cardiovascular health and quality of life.
A diet rich in phytosterols reduces testosterone levels and activity of enzymes that metabolize testosterone into more active forms. The study suggests a potential link between plant-based fats and lower rates of hormone-dependent cancers.
The Prostate Cancer Center of Excellence will focus on improving patient outcomes and offer hope to the more than 10,000 men in North Carolina diagnosed with the disease. The $5 million grant will fund new positions, labs, and studies addressing prevention and treatment aspects.
A study conducted by University of California San Francisco expert Mac Roach found that high-risk prostate cancer patients who receive hormonal therapy in conjunction with radiotherapy have a 20% higher survival rate after eight years compared to those receiving radiotherapy alone. This suggests that prostate cancer patients may need t...
A team of international researchers has pinpointed the site of the first gene for prostate cancer located on the human X chromosome. This discovery may account for almost 20 percent of disease in families with a strong history of the cancer.
A study found that high-risk prostate cancer patients treated with seed implant therapy had poorer outcomes compared to radical prostectomy and external beam radiation. The researchers suggest that high-risk patients should discuss alternative treatment options with their physicians.
DHEA supplements, believed to have anti-aging properties, may stimulate the production of IGF-1, increasing prostate cancer risk. Dr. Goldberg recommends monitoring serum DHEA, PSA, and IGF-1 levels for men taking DHEA supplements.
Researchers identified two distinct forms of prostate cancer, with one being more aggressive. The study also found that p27 plays a role in Benign Prostate Hyperplasia (BPH), which is genetically different from prostate cancer and not a precursor to its development.
A Northwestern University Medical School study found that low literacy levels were a significant predictor of having incurable prostate cancer among low-income white and black men. Poor reading skills were more prevalent among black men with advanced cancers, suggesting low literacy as a key factor in the disparity.
Researchers at the University of Pennsylvania Cancer Center have identified a genetic mutation in the CYP3A4 gene associated with prostate cancer progression. Men carrying this mutation are nearly 10 times more likely to develop advanced tumors, highlighting the potential for targeted prevention strategies.
The new technology enables doctors to assess pubic arch interference in minutes, allowing for better treatment decisions. It also reduces the need for expensive CT scans, which can cost up to $500 and take a week or more to obtain results.
A new study by USC/Norris Cancer Center scientists raises questions about the potential use of finasteride to prevent prostate cancer. Finasteride, commonly used to treat benign prostate disease, may not be effective as a chemopreventive agent against prostate cancer in men with high PSA levels.
A new molecule, Bin1, has been identified by Wistar scientists as a potential indicator of malignant prostate cancer. Bin1 interacts with and limits the malignant potential of Myc, a protein found frequently in prostate cancers.
Researchers found that anti-androgen drugs can trigger the protein that makes prostate and cancerous cells grow, leading to a possible explanation for why hormone therapy loses effectiveness after one or two years. The study suggests that more research is needed to confirm the results.
A new study by Johns Hopkins researchers found that older men have more extensive prostate disease even if their PSA levels are the same as younger men. The study suggests that age should be an additional guide in deciding whether to do further testing for non-palpable prostate cancer.
A new test measuring free PSA can accurately identify men at risk of prostate cancer, allowing for targeted biopsies and reducing unnecessary procedures. The test aims to cut the cost of prostate screening dramatically while sparing men from potential complications like infection and bleeding.
A new version of the PSA test detects 95% of prostate cancers and helps distinguish between cancer and benign conditions. The study reduces unnecessary biopsies and provides personalized risk assessments for men with borderline results.
Scientists at Duke University discovered a genetic switch that governs prostate cancer progression. The switch controls the production of FGF-R2 receptors, which can lead to
The FDA panel unanimously approved a new test for detecting prostate cancer, which catches almost all cancers and reduces unnecessary biopsies. The free PSA test, measuring unbound PSA in the blood, identifies patients who could benefit from surgery or treatments, reducing cancer-free men's biopsies by 20%.
Researchers found that high 'free' testosterone levels in adulthood and a small shoulder span may be related to hormone levels at various stages of development, suggesting a link between these factors and prostate cancer risk. Further study is needed to confirm these findings.
A new study of over 1,000 prostate cancer patients found that those who underwent surgery had remarkably good outcomes, with few reporting dissatisfaction or problems with urinary or sexual function. Despite fears about complications, most men felt healthier and satisfied with their treatment after surgery.
A new study by Washington University School of Medicine researchers found that a surprising 22 percent of men with prostate cancer had PSA levels between 2.6 and 4, highlighting the need for yearly PSA tests for men over 50. The study suggests that doctors may be missing cancers in this range due to outdated guidelines.
A new study by Johns Hopkins Medicine recommends reducing the annual frequency of prostate-specific antigen (PSA) testing for men between 50 and 70 years old, as most don't need frequent tests to detect curable cancers. The guidelines suggest PSA testing every two years is sufficient to identify most men with curable prostate cancer.
The newly revised nomograms combine clinical stage, Gleason score, and PSA level information to identify men who can be cured by surgery alone. The use of these nomograms should improve our ability to predict surgical curability and help patients make informed treatment decisions.
Researchers at the University of Pittsburgh Cancer Institute have found that vitamin D significantly reduces prostate cancer growth in rats. Tumors in treated rats were 88% smaller than those in control rats, and lung metastases were also reduced.
Researchers found that a lower free-to-total PSA ratio may indicate aggressive prostate cancer. The study suggests this ratio can help doctors distinguish between serious and non-serious cases, leading to better treatment decisions.
A new study predicts prostate cancer up to six years earlier than current methods by analyzing the ratio of free to total prostate-specific antigen (PSA) in a man's blood. The research, published in 1996, showed that men with high total PSA levels may have prostate cancer or benign prostatic hypertrophy.
Scientists have identified a major gene, HPC-1, that predisposes men to prostate cancer, located on chromosome 1. The gene is believed to contribute to at least a third of familial prostate cancer cases.
Researchers at the University of Chicago Medical Center have found that testosterone can shrink experimental human prostate tumors that no longer depend on the hormone. This suggests a potential new approach for treating advanced prostate cancer.
A multi-institutional study found that surgery is effective for localized prostate cancer, with tumor grade being the best predictor of long-term survival. Ten years after surgery, men with grade 1 tumors had a 6% mortality rate, while those with grade 2 and 3 tumors had 20% and 23% mortality rates, respectively.
Stanford researchers are working on a new PSA test that can distinguish between cancerous and non-cancerous prostate enlargement. By analyzing the PSA protein extracted from enlarged prostates, they aim to eliminate unnecessary biopsies. The team's approach has shown promising results, reducing false positives by up to 86%.